» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome >
VOL. 127 | NO. 226 | Monday, November 19, 2012

Wright Medical to Buy BioMimetic for $190 Million

The Associated Press

Print | Front Page | Email this story | Comments ()

Medical device maker Wright Medical Group Inc. plans to buy BioMimetic Therapeutics Inc. in a $190 million cash-and-stock deal to help grow its foot and ankle business.

The companies said Monday the deal could grow to $380 million if some incentives are met.

Wright Medical, based in Arlington, Tenn., said it will pay $1.50 in cash and a portion of its stock for each share of BioMimetic. That totals $6.47 per share, based on Wright Medical's Friday closing price of $20.01.

That per-share price represents a premium of 56 percent based on BioMimetic's Friday closing price of $4.15, and the company's shares rose 76 percent, or $3.15, to $7.30 in premarket trading.

BioMimetic shareholders also could receive an additional $6.50 per share if the Food and Drug Administration approves the Franklin, Tenn., company's Augment Bone Graft and if company products reach a couple of sales targets.

The FDA is reviewing the Augment Bone Graft for use in foot and ankle fusions.

The companies say the deal is expected to close in next year's first quarter. The boards of directors for both firms have unanimously approved it, but the transaction still needs BioMimetic shareholder approval.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Sign-Up For Our Free Email Edition
Get the news first with our daily email


 
Blog News, Training & Events
RECORD TOTALS DAY WEEK YEAR
PROPERTY SALES 74 360 18,823
MORTGAGES 96 570 24,194
FORECLOSURE NOTICES 0 0 2,278
BUILDING PERMITS 142 808 40,603
BANKRUPTCIES 68 229 14,122
BUSINESS LICENSES 27 78 5,820
UTILITY CONNECTIONS 0 281 21,803
MARRIAGE LICENSES 11 31 5,062

Weekly Edition

Issues | About

The Memphis News: Business, politics, and the public interest.